1 - 1 / 1 1 |
1. Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Krošelj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek, 2023, original scientific article Keywords: technetium-99m, somatostatin receptor antagonists, kit formulation, single dose toxicity, SPECT, radiopharmaceuticals, neuroendocrine neoplasms |